Get streamlined answers to take action fast, with comprehensive germline testing, tumor profiling, and companion diagnostic HRD testing.
Myriad’s clinically actionable, comprehensive germline and somatic genetic tests help you determine the most effective treatments based on unique cancer features—improving each patient’s chance for a healthy future.
I’m a provider
I’m a patient
Advancing surgical outcomes for germline testing
Your patients need your treatment guidance, fast. MyRisk® Hereditary Cancer Test draws on Myriad’s 30+ years of genetic expertise to analyze 48 clinically actionable genes across 11 cancer types, and gives you the industry’s most accurate and actionable germline result.
Elevate patient care for those with cancer, and those needing preventive intervention.
Find out more about MyRisk Hereditary Cancer Test.
Learn more
Comprehensive germline and somatic biomarker testing from a single, trusted source
Your patients need every step toward cancer treatment to happen quickly. Get streamlined answers to take action fast, with comprehensive germline testing, tumor profiling, and companion diagnostic HRD testing.
Save precious time by identifying comprehensive treatment options, fast.
Find out more about Myriad’s comprehensive germline and somatic testing.
Germline hereditary cancer test capable of identifying risk and providing insights for treatment options for 11 hereditary cancers.
Precise™ Tumor is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.
Genomic prognostic test for patients newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer.
Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.
The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer.
FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer.
FDA-approved assay to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab*
Offered together with Precise Tumor™ to measure protein expression and identify patients who may benefit from immunotherapy
Industry’s lowest rate of BRCA1/2 variants of uncertain significance1,2 for the accuracy you need.
Find out more about our lifetime commitment to variant classification.
Industry’s lowest rate of BRCA1/2 variants of uncertain significance 1,2 for the accuracy you need.
Many patients pay $0 for genetic testing.
Patients will know what their costs are—if any—before the test is run.
Myriad offers assistance to manage out-of-pocket costs.
OPTIONS
INCLUDES
Myriad conducts industry-leading, innovative genetic research and testing to further the science of care. Our scientific studies have been published in prominent journals and at global conferences and feature breakthrough insights for improved patient treatments and outcomes.
Request more information from our team.